Back

In Utero CFTR Modulation Alleviates Disease in G551D Cystic Fibrosis Pigs

Ernst, S. E.; Meyerholz, D. K.; Samuel, M. S.; Whitworth, K. M.; Naguib, Y. W.; Nakhla, D. S.; Abou Alaiwa, M. H.; Randak, C. O.; Dong, Q.; Ostedgaard, L. S.; Rehman, T.; Hilkin, B. M.; Powers, L. S.; Stroik, M. R.; Gansemer, N. D.; Rector, M. R.; Taft, P. J.; Hedinger, R.; Goodell, B. J.; Mather, S. E.; Sen, R.; Thornell, I. M.; Bullard, S. A.; Cecil, R. F.; Benne, J. A.; Ash, J. J.; Boyken, L. D.; Karp, P. H.; Tan, P.; Wu, S.; Fischer, A. J.; Cooney, A. L.; Sinn, P. L.; Pezzulo, A. A.; Lee, K.; McCray, P. B.; Zabner, J.; Salem, A. K.; Prather, R. S.; Welsh, M. J.; Stoltz, D. A.

2026-01-21 physiology
10.64898/2026.01.20.698888 bioRxiv
Show abstract

Previous studies indicate that pigs with CFTR-null and CFTR-{Delta}F508 mutations develop multiorgan disease similar to that in people with cystic fibrosis (CF). At birth, their airways exhibit host defense defects that predispose to airway infection, inflammation, and mucus accumulation. The CFTR-G551D mutation causes CF by producing CFTR channels that localize correctly but have reduced channel activity. Ivacaftor (VX-770) is a small molecule drug developed to potentiate CFTR activity. To test the phenotype of the CFTR-G551D mutation in pigs and determine whether ivacaftor can rescue CF abnormalities, we developed CFTRG551D/G551D (CF-G551D) pigs through homologous recombination in fetal fibroblasts and somatic cell nuclear transfer. Newborn CF-G551D piglets exhibited phenotypes similar to CF-null piglets, including meconium ileus, exocrine pancreatic destruction, micro-gallbladder, vas deferens destruction, and airway structural abnormalities. Compared to wild-type pigs, CF-G551D pigs had reduced forskolin-stimulated short-circuit current in airway and intestinal tissues. Ivacaftor increased the single-channel open state probability of CFTR-G551D and increased short-circuit current to near wild-type levels. Similar to our other CF pig models, we found that 100% of CF-G551D pigs were born with meconium ileus. To test whether in utero ivacaftor treatment could prevent or alleviate meconium ileus, pregnant sows were treated with ivacaftor beginning at day 35 of gestation and continuing until delivery. This treatment rescued the pancreas, gallbladder, and vas deferens phenotype in the majority of CF-G551D pigs. Animals that were spared from meconium ileus were able to survive without ivacaftor treatment. Airway disease developed similar to other CF pig models. These findings indicate that this model may be useful for studies in which CFTR function can be reversed, for investigating in utero CFTR correction strategies, and for longitudinal studies in CF pigs.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Journal of Cystic Fibrosis
15 papers in training set
Top 0.1%
18.2%
2
American Journal of Respiratory Cell and Molecular Biology
38 papers in training set
Top 0.1%
14.0%
3
Disease Models & Mechanisms
119 papers in training set
Top 0.2%
6.2%
4
American Journal of Physiology-Lung Cellular and Molecular Physiology
39 papers in training set
Top 0.1%
6.2%
5
European Respiratory Journal
54 papers in training set
Top 0.3%
6.2%
50% of probability mass above
6
Scientific Reports
3102 papers in training set
Top 20%
6.2%
7
JCI Insight
241 papers in training set
Top 0.9%
4.2%
8
PLOS ONE
4510 papers in training set
Top 45%
2.5%
9
eLife
5422 papers in training set
Top 39%
1.8%
10
Physiological Reports
35 papers in training set
Top 0.5%
1.7%
11
International Journal of Molecular Sciences
453 papers in training set
Top 9%
1.5%
12
Molecular Therapy
71 papers in training set
Top 2%
1.2%
13
Respiratory Research
19 papers in training set
Top 0.3%
1.2%
14
iScience
1063 papers in training set
Top 25%
0.9%
15
npj Genomic Medicine
33 papers in training set
Top 0.7%
0.9%
16
Heart Rhythm
22 papers in training set
Top 0.6%
0.9%
17
The FASEB Journal
175 papers in training set
Top 2%
0.9%
18
Journal of Lipid Research
35 papers in training set
Top 0.4%
0.9%
19
Journal of Clinical Investigation
164 papers in training set
Top 5%
0.9%
20
PLOS Genetics
756 papers in training set
Top 13%
0.9%
21
Frontiers in Physiology
93 papers in training set
Top 6%
0.7%
22
Nature Communications
4913 papers in training set
Top 64%
0.7%
23
Cells
232 papers in training set
Top 7%
0.7%
24
Pediatric Pulmonology
14 papers in training set
Top 0.4%
0.7%
25
Molecular Therapy - Nucleic Acids
24 papers in training set
Top 0.4%
0.7%
26
Human Mutation
29 papers in training set
Top 0.8%
0.7%
27
Physiological Genomics
15 papers in training set
Top 0.4%
0.7%
28
Stem Cell Reports
118 papers in training set
Top 1%
0.6%
29
Nucleic Acids Research
1128 papers in training set
Top 20%
0.6%
30
Cellular and Molecular Life Sciences
84 papers in training set
Top 1%
0.6%